These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35983042)

  • 1. Clinical impact and a prognostic marker of early rituximab treatment after rituximab reimbursement in Korean pemphigus patients.
    Song A; Jang J; Lee A; Min SY; Lee SG; Kim SC; Shin J; Kim JH
    Front Immunol; 2022; 13():932909. PubMed ID: 35983042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab and Corticosteroid Effect on Desmoglein-Specific B Cells and Desmoglein-Specific T Follicular Helper Cells in Pemphigus.
    Maho-Vaillant M; Perals C; Golinski ML; Hébert V; Caillot F; Mignard C; Riou G; Petit M; Viguier M; Hertl M; Boyer O; Calbo S; Fazilleau N; Joly P
    J Invest Dermatol; 2021 Sep; 141(9):2132-2140.e1. PubMed ID: 33766510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Infection in Pemphigus Vulgaris Two Weeks after Rituximab Therapy with Total Recovery: A Case Report.
    Róbert L; Kovács A; Sárdy M; Fábián M
    Acta Dermatovenerol Croat; 2023 Dec; 31(3):156-157. PubMed ID: 38439728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modifications of the Transcriptomic Profile of Autoreactive B Cells From Pemphigus Patients After Treatment With Rituximab or a Standard Corticosteroid Regimen.
    Hébert V; Petit M; Maho-Vaillant M; Golinski ML; Riou G; Derambure C; Boyer O; Joly P; Calbo S
    Front Immunol; 2019; 10():1794. PubMed ID: 31440235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response.
    Colliou N; Picard D; Caillot F; Calbo S; Le Corre S; Lim A; Lemercier B; Le Mauff B; Maho-Vaillant M; Jacquot S; Bedane C; Bernard P; Caux F; Prost C; Delaporte E; Doutre MS; Dreno B; Franck N; Ingen-Housz-Oro S; Chosidow O; Pauwels C; Picard C; Roujeau JC; Sigal M; Tancrede-Bohin E; Templier I; Eming R; Hertl M; D'Incan M; Joly P; Musette P
    Sci Transl Med; 2013 Mar; 5(175):175ra30. PubMed ID: 23467561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal Outcomes after Rituximab Therapy for Pemphigus Vulgaris.
    Tovanabutra N; Bax CE; Feng R; Kushner CJ; Payne AS
    J Invest Dermatol; 2022 Apr; 142(4):1058-1064.e7. PubMed ID: 34710389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in pemphigus.
    Hebert V; Joly P
    Immunotherapy; 2018 Jan; 10(1):27-37. PubMed ID: 29064314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab.
    Sinagra JL; Vedovelli C; Binazzi R; Salemme A; Moro F; Mazzanti C; Didona B; Di Zenzo G
    Front Immunol; 2021; 12():665522. PubMed ID: 33936104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab - Progress but Still Not a Final Resolution for Pemphigus Patients: Clinical Report From a Single Center Study.
    Miše J; Jukić IL; Marinović B
    Front Immunol; 2022; 13():884931. PubMed ID: 35592312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pathogenic activity of anti-desmoglein autoantibodies parallels disease severity in rituximab-treated patients with pemphigus vulgaris.
    Sinistro A; Calabresi V; Lupi F; Sera F; Frezzolini A; Ruffelli M; De Pità O; Camaioni D; Cianchini G; Di Zenzo G
    Eur J Dermatol; 2015; 25(6):578-85. PubMed ID: 26552329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab.
    Albers LN; Liu Y; Bo N; Swerlick RA; Feldman RJ
    J Am Acad Dermatol; 2017 Dec; 77(6):1074-1082. PubMed ID: 28927663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).
    Marzano AV; Fanoni D; Venegoni L; Berti E; Caputo R
    Dermatology; 2007; 214(4):310-8. PubMed ID: 17460402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab in the Management of Autoimmune Bullous Diseases: A Treatment-Resistant Case Series from a Single Central European Referral Center.
    Spałek MM; Jałowska M; Bowszyc-Dmochowska M; Dmochowski M
    Medicina (Kaunas); 2024 Feb; 60(2):. PubMed ID: 38399557
    [No Abstract]   [Full Text] [Related]  

  • 14. Pemphigus: Current and Future Therapeutic Strategies.
    Didona D; Maglie R; Eming R; Hertl M
    Front Immunol; 2019; 10():1418. PubMed ID: 31293582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab therapy for intractable pemphigus: A multicenter, open-label, single-arm, prospective study of 20 Japanese patients.
    Yamagami J; Kurihara Y; Funakoshi T; Saito Y; Tanaka R; Takahashi H; Ujiie H; Iwata H; Hirai Y; Iwatsuki K; Ishii N; Sakurai J; Abe T; Takemura R; Mashino N; Abe M; Amagai M
    J Dermatol; 2023 Feb; 50(2):175-182. PubMed ID: 36196051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultra-low dose rituximab for refractory pemghigus vulgaris: a pilot study.
    Russo I; Miotto S; Saponeri A; Alaibac M
    Expert Opin Biol Ther; 2020 Jun; 20(6):673-678. PubMed ID: 32027810
    [No Abstract]   [Full Text] [Related]  

  • 17. Rituximab and intravenous immunoglobulin as alternatives to long-term systemic corticosteroids in the treatment of pemphigus: a single center case series of 63 patients.
    Brown AE; Motaparthi K; Hsu S
    Dermatol Online J; 2018 Jan; 23(12):. PubMed ID: 29447653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modifications of the BAFF/BAFF-Receptor Axis in Patients With Pemphigus Treated With Rituximab Versus Standard Corticosteroid Regimen.
    Hébert V; Maho-Vaillant M; Golinski ML; Petit M; Riou G; Boyer O; Musette P; Calbo S; Joly P
    Front Immunol; 2021; 12():666022. PubMed ID: 34054835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.
    Ahmed AR; Spigelman Z; Cavacini LA; Posner MR
    N Engl J Med; 2006 Oct; 355(17):1772-9. PubMed ID: 17065638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single cycle of rituximab for the treatment of severe pemphigus.
    Joly P; Mouquet H; Roujeau JC; D'Incan M; Gilbert D; Jacquot S; Gougeon ML; Bedane C; Muller R; Dreno B; Doutre MS; Delaporte E; Pauwels C; Franck N; Caux F; Picard C; Tancrede-Bohin E; Bernard P; Tron F; Hertl M; Musette P
    N Engl J Med; 2007 Aug; 357(6):545-52. PubMed ID: 17687130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.